Development of a Transcription Factor-Based Prognostic Model for Predicting the Immune Status and Outcome in Pancreatic Adenocarcinoma

Zhang, Xianbin; Li, Li; Liu, Peng; Tian, Yu; Gong, Peng

doi:https://doi.org/10.1155/2022/4946020

Journal of Immunology Research

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusion Data Availability Conflicts of Interest Authors’ Contributions Acknowledgments References Copyright Related Articles

Special Issue

Exploration of Novel Potential Biomarkers for Cancer Immunotherapy

View this Special Issue

Research Article | Open Access

Volume 2022 | Article ID 4946020 | https://doi.org/10.1155/2022/4946020

Development of a Transcription Factor-Based Prognostic Model for Predicting the Immune Status and Outcome in Pancreatic Adenocarcinoma

Xianbin Zhang,^1,2,3Li Li,¹Peng Liu,¹Yu Tian,^1,4and Peng Gong^1,3

Academic Editor: Fu Wang

Received18 Feb 2022

Accepted19 Mar 2022

Published05 May 2022

Abstract

Pancreatic adenocarcinoma (PAAD) is the most common primary malignancy of the pancreas. Growing studies indicate that transcription factors (TFs) are abnormally expressed in PAAD. We, therefore, aimed to evaluate the effect of TFs in PAAD and develop a TF-based prognostic signature for the patients. The expression of the TFs and the clinical characteristics were obtained from TCGA datasets. The levels of the TFs were evaluated in PAAD tissues or nontumor tissues. Kyoto Encyclopedia of Genes and Genomes (KEGG) was used to determine the potential function of the dysregulated TFs. To create a prognostic signature, we used univariate and multivariate Cox regression. In addition, the relationship between risk score and tumor microenvironment was analyzed. In this study, we observed 19 increased and 10 decreased TFs in PAAD tissues. KEGG assays indicated that dysregulated TFs were involved in transcriptional misregulation in cancer. Multivariate Cox analysis identified two prognostic factors, Zinc finger protein 488 and BCL11A; and we developed a risk score model by these two factors. The Kaplan-Meier estimator suggested that patients with high risk exhibited a shorter overall survival than those with low risk. The receiver operating characteristic curve proved that the accuracy of this prognostic signature was 0.686 in predicting the 5-year survival. In addition, we observed that the high score was distinctly related to advanced tumor stage and immune infiltrates. Taken together, we developed a novel TF-related model which could be applied as a potential prognostic tool for PAAD and may guide the choice of immunotherapies.

1. Introduction

Worldwide, more than half a million people die each year from pancreatic adenocarcinoma (PAAD), the most malignant tumor of the digestive system [1–3]. PAAD is associated with many risk factors including smoking, alcohol, gallstones, and chronic pancreatitis. Serum carbohydrate antigen is the most commonly used test to determine PAAD [4]. However, due to the low sensitivity and accuracy of this method, many patients are unable to be detected in the early stages of the tumor. This leads to the five-year overall survival no more than 10% [1, 4]. Therefore, it is important to develop novel tests for the early diagnosis of pancreatic cancer.

To activate or inhibit transcription of genes, transcription factors (TFs) attach to the transactivation or transrepression domains of DNA helix and regulate the genes’ expression by turning on or turning off of the transcription [5–7]. Many biological processes, including the proliferation and death of cells, are regulated by transcription factors [8]. Notably, a variety of TFs was found to be dysregulated in many tumors such as cholangiocarcinoma [9], colon adenocarcinoma [10], and glioblastoma [11]. In addition, recent studies prove that the dysregulated expression of TFs may be involved in the immune functions of several types of carcinomas [12, 13]. This suggests that TFs might be promising diagnostic biomarkers and therapeutic targets in malignancies.

In this study, we aimed to investigate the expression of TFs in PAAD and develop a risk score model, which could be used to diagnose the PAAD and predict the prognosis of patients. Additionally, we evaluated if and how these TFs regulate immune infiltration. In conclusion, we developed a novel TF-based risk score model and this model will support the clinicians to choose the individualized therapeutic strategies for PAAD patients.

2. Materials and Methods

2.1. Biological Microarray Data

The expression of transcription factors was obtained from The Cancer Genome Atlas (TCGA) database. In this study, we choose the data of HTseq-FPKM, and the genetic expressions were presented as . The patients whose follow-up period was less than 30 days were excluded from the study. Finally, we collected 1639 TFs from the study of Lambert et al. [14] and the survival analysis was performed in 172 PAAD patients.

2.2. Evaluating the Prognostic Value of TFs

To determine TFs that were differently expressed between PAAD and nontumor samples, the limma package was used. TFs with a log₂ fold change and adjusted values lower than 0.05 were identified as being differentially expressed. The false discovery rate was controlled by using the Benjamini-Hochberg method, and the R package “ggplot2” was used to construct the volcano charts [15]. The hierarchical cluster analysis was performed with the support of the heat map. The prognostic value of TFs was determined by the univariate and multivariate Cox regression analysis. All TFs were included in the univariate Cox regression, and the TFs which could significantly influence the prognoses of the patients were included in the multivariate Cox analysis.

2.3. Development and Validation of the TF-Related Prognostic Model

To develop the prognostic model, the independent prognostic TFs of PAAD patients were included and the model was developed with the support of the coefficient of the multiple Cox regression. To evaluate the prognosis of this model, the patients were divided into low- and high-risk categories. Kaplan-Meier curves and multivariate Cox regression were applied. The receiver operating characteristic curve (ROC) was used to determine the accuracy of this model in predicting the 5-year survival.

2.4. Evaluating the Relationship between TFs, Immune Infiltration, and Stroma

The infiltrations of immune cells were quantified by ssGSEA and immune scores [16]. The “GSEABase” and “GSVA” packages were used [17], and the enrichment score was obtained. The statistical differences between different groups were determined by Kruskal-Wallis tests. To evaluate the relationship between TFs and immune infiltration or stroma, two-way ANOVA was used.

2.5. Evaluating the Relationship between TFs and Stemness of Cells

Previous studies suggest that the stemness of carcinoma cells can be determined by the RNA-based stemness scores (RNAss) or the DNA methylation-based stemness scores (DNAss) [18]. We obtained the data from TCGA database and evaluated the stemness of the cancer cells by these scores. The values of the score were between 0 and 1. If the score is zero, this suggests that the cancer cells are well differentiated; if the score is one, this suggests that the cells are poorly differentiated and have strong stemness.

2.6. Statistical Methods

The R (version 4.0.3) was used to conduct all statistical analyses. The Wilcoxon tests were used to detect the statistically different expressions of TFs in PAAD tissues and nontumor tissues. The immune scores of different groups were determined by the Mann–Whitney test, and the values were adjusted by the Benjamini-Hochberg method. To determine the survival time of patients, the Kaplan-Meier curve and log-rank test were used. The univariate and multivariate Cox regressions were applied to identify the independent prognostic factor, and a TF-based prognostic score was developed by the coefficient of multivariate Cox regression. The statistical differences between scores of each group were determined by the Mann–Whitney test. Differences with were considered to be significant.

3. Results

3.1. Identification of Differentially Expressed TFs in PAAD

The limma R package was used to determine TFs that exhibited a dysregulated level among 1639 profiles obtained from TCGA [19]. We observed that the expression of 19 TFs increased in the PAAD tissues and 10 TFs decreased (Figures 1(a) and 1(b)). These differentially expressed TFs were further studied by Gene Ontology (GO) and KEGG enrichment analysis. We observed that differentially expressed TFs were enriched in cell fate commitment, pattern specification process, transcription regulator complex, embryonic organ development, transcription repressor complex, protein-DNA complex, and DNA-binding transcription repressor activity (Figure 2(a)). KEGG assays indicated that the dysregulated TFs were involved in transcriptional misregulation in cancer (Figure 2(b)).

(a)

(b)

(a)

(b)

3.2. ZNF488 and BCL11A Are Independent Prognostic Factors of PAAD

To determine the prognostic TFs in PAAD, we performed the univariate Cox regression with the 29 dysregulated TFs in PAAD. We observed that Zinc finger protein 488 (ZNF488) and Ovo-like transcriptional repressor 1 (OVOL1) slightly increased the risk of death and BAF chromatin remodeling complex subunit, BCL11A, minor improved the prognosis of the patients (Figure 3(a)). The multivariate Cox regression suggested that ZNF488 and BCL11A were the independent prognostic factors for PAAD patients (Figure 3(b)).

(a)

(b)

3.3. Develop and Evaluate the TF-Based Prognostic Model

We used the coefficient of TFs and developed a model to predict the prognosis of patients (). Based on the median score, all cases were divided into a high-risk group or a low-risk group. The expression of ZNF488 and BCL11A is presented in Figure 4(a), and the survival times of patients are presented in Figures 4(b) and 4(c). The Kaplan-Meier curve suggested that the survival time of patients with high-risk scores was significantly shorter than those with low-risk scores (Figure 4(d)). The ROC curve and the area under the curve indicated that the accuracy of this score in predicting the 5-year survival of patients was 0.686 (Figure 4(e)). In addition, the univariate and multivariate Cox regression suggested that the prognostic model was an independent prognostic factor of PAAD patients (Figures 5(a) and 5(b)).

(a)

(b)

(c)

(d)

(e)

(a)

(b)

3.4. The Relationship between the Prognostic Model and Clinical Features

We further analyzed the association between the prognostic model and the clinical features. We observed that there were no significant differences between young patients and elderly patients (Figure 6(a)), female and male (Figure 6(b)), grade 1/grade 2 tumors, and grade 3/grade 4 tumors (Figure 6(c)). Interestingly, we observed that the risk of patients with the middle stage of tumors or advanced stage of tumors was significantly high than that with early stage of tumors (Figure 6(d)).

(a)

(b)

(c)

(d)

3.5. The Relationship between the Prognostic Model and Immune Infiltration

To evaluate if TFs were involved in the immune infiltration, we evaluated the relationship between the risk score and the immune status; we observed that compared to the low-risk group (blue box), the level of tumor-infiltrating lymphocytes (TIL), Th1 cells, T follicular helper (Tfh) cells, T helper (Th) cells, plasmacytoid dendritic (pDC) cells, natural killer (NK) cells, neutrophils, mast cells, CD8⁺ T cells, and B cells was significantly decreased in the high-risk group (red box, Figure 7(a)). Additionally, we observed that the level of type II IFN (IFN-γ), T cell costimulation, T cell coinhibition, inflammation-promoting, human leukocyte antigen (HLA), cytolytic activity, and checkpoint and CC chemokine receptor (CCR) were also significantly decreased in the high-risk group (red box, Figure 7(b)). To investigate the relationship between the risk score and the immune infiltration, the level of the risk score was evaluated in six types of immune infiltrations, C1 (wound healing), C2 (INF-γ dominant), C3 (inflammatory), C4 (lymphocyte depleted), C5 (immunologically quiet), and C6 (TGF-β dominant). We observed that C3 had a low risk score when compared to C1 or C2 (Figure 8).

(a)

(b)

3.6. The Relationship between the Prognostic Model and Stemness, Immunological, or Stromal Microenvironment

To evaluate the relationship between the risk score and stemness, immunological, or stromal microenvironment, we calculated the Spearman rank correlation coefficient of the risk score and the scores of stemness, immunology, or stroma. We observed that the risk score was positively associated with RNA-based stemness scores (RNAss, Figure 9(a)) or the DNA methylation-based stemness scores (DNAss, Figure 9(b)) and negatively associated with the stromal score (Figure 10(a)) and immune score (Figure 10(b)). This suggested that the risk score increased the stemness of tumors and impaired the immunological or stromal microenvironment.

(a)

(b)

(a)

(b)

4. Discussion

PAAD is the most aggressive and fatal tumor [20, 21]. Due to the lack of a sensitive and specific test of PAAD, the tumors have already spread from the pancreas to the liver and lung [22]. Thus, it needs to develop a novel test that can diagnose PAAD at an early stage and monitor the treatment response. Previous studies reported that TFs are involved in the genesis, development, and metastasis of several tumors, [23, 24] and therefore, TFs are promising biomarkers for the diagnosis of PAAD [25].

In the present study, we observed that ZNF488 and BCL11A were independent prognostic variables of PAAD patients and we developed a predictive model by using these two TFs. The predictive model proved that patients with high-risk scores had a short overall survival. Additionally, the ROC curve indicated that this risk score had an acceptable accuracy in predicting the 5-year survival. The univariate and multivariate Cox regression confirmed that ZNF488 and BCL11A were independent prognostic factors for PAAD patients. This was supported by previous studies [26, 27]. For example, Qiu et al. proved that ZNF488 promotes the invasion and migration of PAAD cells by activating the Akt/mTOR signaling pathway [26]. Zhou et al. found that overexpression of BCL11A promoted the growth of laryngeal squamous cell carcinoma [27]. In addition, we evaluated if and how ZNF488 or BCL11A was involved in the immunological microenvironment. We observed that the level of CD8⁺ T cells significantly decreased in the high-risk group. It is well known that CD8⁺ T cells are the cytotoxic T lymphocytes that kill the carcinoma cells [28]. This may be a possible mechanism that the patients in the high-risk group have a poor prognosis.

It is reported that cancer stem cell-like cells are master contributors to the poor survival of PAAD [29]. We, therefore, evaluated the relationship between the risk score and the stemness of cancer cells. In the process of tumor growth, some tumor cells lose their differentiation potential and gradually have the characteristics of progenitor cells and stem cells. This is due to the high levels of methylation in the DNA of some genes, and previous studies suggest that RNAss and DNAss can accurately reflect the stemness of tumor cells [18]. We observed that the TF-based score was positively correlated with the RNAss or DNAss. This indicates that ZNF488 or BCL11A increases the stemness of cancer cells. To our knowledge, no study reports how ZNF488 regulates the stemness of PAAD cells. Zong et al. find that ZNF488 is an independent prognostic factor of nasopharyngeal carcinoma, and it promotes the adhesion and proliferation of cells by the IV/FAK/AKT/Cyclin D1 pathway [30]. In the future, additional studies could evaluate if IV/FAK/AKT/Cyclin D1 is involved in the ZNF488-induced stemness. Zhu et al. report that BCL11A could enhance stemness by activating the Wnt/β-catenin signaling [31]. Thus, the combinational therapeutic strategies that target the BCL11A and Wnt/β-catenin signaling pathway are a promising treatment for PAAD patients.

5. Conclusion

In conclusion, based on ZNF488 and BCL11A, we developed a prognostic model and the accuracy of this model was 0.686 in predicting the 5-year survival. In addition, we observed that ZNF488 and BCL11A were positively related to the advanced tumor stage and stemness. Targeting ZNF488 and BCL11A may be a promising strategy for the treatment of PAAD.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this study.

Authors’ Contributions

Peng Gong and Yu Tian contributed to the study concept and design of the study; Xianbin Zhang, Yu Tian, Li Li, and Peng Liu performed the analysis and wrote the manuscript; and Peng Gong revised the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The study was supported by the Natural Science Foundation of Shenzhen University General Hospital (Grant number: SUGH2018QD021), Shenzhen Key Medical Discipline Construction Fund & Sanming Project of Medicine in Shenzhen (SZSM202111002), the Project of Department of Education of Guangdong Province (2018KTSCX193 and 2020KZDZX1170), Guangdong Basic and Applied Basic Research Fund (Guangdong Natural Science Fund; Grant number: 2020A1515110083), and Shenzhen Science and Technology Innovation Commission (Grant numbers: RCBS20200714114958333 and JCYJ20190808114203755).

References

R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2021,” CA: a Cancer Journal for Clinicians, vol. 71, no. 1, pp. 7–33, 2021.
View at: Publisher Site | Google Scholar
M. N. Mavros, D. Moris, P. J. Karanicolas, M. H. G. Katz, E. M. O’Reilly, and T. M. Pawlik, “Clinical trials of systemic chemotherapy for resectable pancreatic cancer: a review,” JAMA Surgery, vol. 156, no. 7, pp. 663–672, 2021.
View at: Publisher Site | Google Scholar
A. A. Connor and S. Gallinger, “Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data,” Nature Reviews. Cancer, vol. 22, no. 3, pp. 131–142, 2022.
View at: Publisher Site | Google Scholar
J. P. Neoptolemos, C. Springfeld, and T. Hackert, “A review of pancreatic cancer,” Journal of the American Medical Association, vol. 326, no. 23, p. 2436, 2021.
View at: Publisher Site | Google Scholar
K. Takahashi and S. Yamanaka, “A decade of transcription factor-mediated reprogramming to pluripotency,” Nature Reviews. Molecular Cell Biology, vol. 17, no. 3, pp. 183–193, 2016.
View at: Publisher Site | Google Scholar
F. Spitz and E. E. Furlong, “Transcription factors: from enhancer binding to developmental control,” Nature Reviews. Genetics, vol. 13, no. 9, pp. 613–626, 2012.
View at: Publisher Site | Google Scholar
M. E. Daly, “Transcription factor defects causing platelet disorders,” Blood Reviews, vol. 31, no. 1, pp. 1–10, 2017.
View at: Publisher Site | Google Scholar
J. Simicevic and B. Deplancke, “Transcription factor proteomics-tools, applications, and challenges,” Proteomics, vol. 17, no. 3-4, pp. 1–11, 2017.
View at: Publisher Site | Google Scholar
I. M. Moya, S. A. Castaldo, L. Van den Mooter et al., “Peritumoral activation of the hippo pathway effectors YAP and TAZ suppresses liver cancer in mice,” Science, vol. 366, no. 6468, pp. 1029–1034, 2019.
View at: Publisher Site | Google Scholar
K. Kawasaki, K. Toshimitsu, M. Matano et al., “An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping,” Cell, vol. 183, no. 5, pp. 1420–1435.e21, 2020.
View at: Publisher Site | Google Scholar
T. Chu, E. J. Rice, G. T. Booth et al., “Chromatin run-on and sequencing maps the transcriptional regulatory landscape of glioblastoma multiforme,” Nature Genetics, vol. 50, no. 11, pp. 1553–1564, 2018.
View at: Publisher Site | Google Scholar
C. Ferreira, J. Estaquier, and R. Silvestre, “Immune-metabolic interactions between Leishmania and macrophage host,” Current Opinion in Microbiology, vol. 63, pp. 231–237, 2021.
View at: Publisher Site | Google Scholar
H. Yu, D. Pardoll, and R. Jove, “STATs in cancer inflammation and immunity: a leading role for STAT3,” Nature Reviews. Cancer, vol. 9, no. 11, pp. 798–809, 2009.
View at: Publisher Site | Google Scholar
S. A. Lambert, A. Jolma, L. F. Campitelli et al., “The human transcription factors,” Cell, vol. 175, no. 2, pp. 598-599, 2018.
View at: Publisher Site | Google Scholar
K. Ito and D. Murphy, “Application ofggplot2to pharmacometric graphics,” CPT: Pharmacometrics & Systems Pharmacology, vol. 2, no. 10, article e79, 2013.
View at: Publisher Site | Google Scholar
M. Yi, D. V. Nissley, F. McCormick, and R. M. Stephens, “ssGSEA score-based Ras dependency indexes derived from gene expression data reveal potential Ras addiction mechanisms with possible clinical implications,” Scientific Reports, vol. 10, no. 1, article 10258, 2020.
View at: Publisher Site | Google Scholar
S. Hänzelmann, R. Castelo, and J. Guinney, “GSVA: gene set variation analysis for microarray and RNA-seq data,” BMC Bioinformatics, vol. 14, no. 1, p. 7, 2013.
View at: Publisher Site | Google Scholar
X. Yang, Y. Miao, J. Wang, and D. Mi, “A pan-cancer analysis of the HER family gene and their association with prognosis, tumor microenvironment, and therapeutic targets,” Life Sciences, vol. 273, p. 119307, 2021.
View at: Publisher Site | Google Scholar
M. E. Ritchie, B. Phipson, D. I. Wu et al., “limma powers differential expression analyses for RNA-sequencing and microarray studies,” Nucleic Acids Research, vol. 43, no. 7, 2015.
View at: Google Scholar
R. M. Thomas and C. Jobin, “Microbiota in pancreatic health and disease: the next frontier in microbiome research,” Nature Reviews. Gastroenterology & Hepatology, vol. 17, no. 1, pp. 53–64, 2020.
View at: Publisher Site | Google Scholar
K. Kothari, C. Lopes Vendrami, L. C. Kelahan, J. S. Shin, P. Mittal, and F. H. Miller, “Inflammatory mimickers of pancreatic adenocarcinoma,” Abdominal Radiology, vol. 45, no. 5, pp. 1387–1396, 2020.
View at: Publisher Site | Google Scholar
X. Zhang, P. Liu, Y. Shang et al., “Metformin and LW6 impairs pancreatic cancer cells and reduces nuclear localization of YAP1,” Journal of Cancer, vol. 11, no. 2, pp. 479–487, 2020.
View at: Publisher Site | Google Scholar
N. Albadari, S. Deng, and W. Li, “The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy,” Expert Opinion on Drug Discovery, vol. 14, no. 7, pp. 667–682, 2019.
View at: Publisher Site | Google Scholar
S. Goossens, N. Vandamme, P. Van Vlierberghe, and G. Berx, “EMT transcription factors in cancer development re-evaluated: beyond EMT and MET,” Biochimica Et Biophysica Acta. Reviews on Cancer, vol. 1868, no. 2, pp. 584–591, 2017.
View at: Publisher Site | Google Scholar
J. E. Bradner, D. Hnisz, and R. A. Young, “Transcriptional addiction in cancer,” Cell, vol. 168, no. 4, pp. 629–643, 2017.
View at: Publisher Site | Google Scholar
H. Qiu, L. Zhang, D. Wang et al., “ZNF488 promotes the invasion and migration of pancreatic carcinoma cells through the Akt/mTOR pathway,” Computational and Mathematical Methods in Medicine, vol. 2022, Article ID 4622877, 9 pages, 2022.
View at: Publisher Site | Google Scholar
J. Zhou, L. Zhou, D. Zhang et al., “BCL11A promotes the progression of laryngeal squamous cell carcinoma,” Frontiers in Oncology, vol. 10, p. 375, 2020.
View at: Publisher Site | Google Scholar
C. Xu, S. Sui, Y. Shang et al., “The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma,” Journal of Advanced Research, vol. 24, pp. 139–148, 2020.
View at: Publisher Site | Google Scholar
J. Peng, B. F. Sun, C. Y. Chen et al., “Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma,” Cell Research, vol. 29, no. 9, pp. 725–738, 2019.
View at: Publisher Site | Google Scholar
D. Zong, N. Jiang, J. H. Xu et al., “ZNF488 is an independent prognostic indicator in nasopharyngeal carcinoma and promotes cell adhesion and proliferation via collagen IV/FAK/AKT/cyclin D1 pathway,” Cancer Management and Research, vol. 11, pp. 5871–5882, 2019.
View at: Publisher Site | Google Scholar
L. Zhu, R. Pan, D. Zhou, G. Ye, and W. Tan, “BCL11A enhances stemness and promotes progression by activating Wnt/β-catenin signaling in breast cancer,” Cancer Management and Research, vol. 11, pp. 2997–3007, 2019.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2022 Xianbin Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

292

Downloads

460

Citations